Showing 6811-6820 of 8179 results for "".
- AbbVie’s Rinvoq Performs Well in Head-to-Head Phase 3b AD Studyhttps://practicaldermatology.com/news/abbvies-rinvoq-performs-well-in-head-to-head-phase3b-ad-study/2460630/Topline results from the phase 3b “Heads Up” study show that a greater proportion of subjects treated with AbbVie’s Rinvoq (upadacitinib 30mg, once daily) achieved at least a 75 percent improvement in the Eczema Area Severity Index (EASI 75) at week 16, compared to dupilumab (30
- Are Sunscreens Overstating Their SPF?https://practicaldermatology.com/news/are-sunscreens-overstating-their-spf/2460629/One out of 12 sunscreens worldwide are likely overstating their sun protection factor, according to research from What’s In My Jar, a London-based AI-powered skincare startup. Using machine learning, What’s In My Jar analyzed formulas of 1,205 sunscreen products in thei
- Colleen Goggins Joins ZO Skin Health's Board Of Directorshttps://practicaldermatology.com/news/colleen-goggins-joins-zo-skin-healths-board-of-directors-following-majority-investment-by-blackstone/2460624/Colleen Goggins is joining ZO Skin Health’s board of directors. This follows the recent acquisition of a majority stake in the business in October by funds managed by Blackstone Tactical Opportunities. As a partner and counsellor to a large variety of bu
- IPC Weighs In On COVID-19 Vaccine Safety and Psoriasishttps://practicaldermatology.com/news/ipc-weighs-in-on-covid-19-vaccine-safety-and-psoriasis/2460623/The International Psoriasis Council (IPC) released guidance on the potential impact of psoriasis therapy, particularly systemic therapy, on a SARS-CoV-2 vaccine. The principal considerations for SARS-CoV-2 vaccines are the same as for any vaccine, the IPC notes. Avo
- NRS Awards 2020 Research Grantshttps://practicaldermatology.com/news/nrs-awards-2020-research-grants/2460622/Expect to learn more about the genome of the Demodex mite, the microbiome’s role in rosacea, and the skin and eyelid lipid content of individuals with rosacea.The National Rosacea Society has awarded funding for studies—two new, plus continuing support for one ongoing study—into
- Dupixent Approved by European Commission as First and Only Biologic Medicine for Children Aged 6 to 11 Years with Severe ADhttps://practicaldermatology.com/news/dupixent-approved-by-european-commission-as-first-and-only-biologic-medicine-for-children-aged-6-to-11-years-with-severe-ad/2460619/The European Commission (EC) has given its nod to Dupixent (dupilumab) for children 6 to 11 with severe atopic dermatitis who are candidates for systemic therapy. Dupixent is the only systemic medicine approved in the EU to treat these patients. "As the parent
- Crown Aesthetics Scores Class IIa CE Certification for SkinPen Precision from British Standards Institutionhttps://practicaldermatology.com/news/crown-aesthetics-scores-class-iia-ce-certification-for-skinpen-precision/2460614/The British Standards Institution (BSI) granted a Class IIa CE Certification mark to Crown Aesthetics’ SkinPen Precision. The certification confirms SkinPen as a treatment to improve the appearance of facial acne scars in adults aged 22 years or older and to improve the appe
- More Positive Phase 3 Data for Pfizer's Abrocitinib in ADhttps://practicaldermatology.com/news/more-positive-phase-3-data-for-pfizers-abrocitinib-in-ad/2460607/Positive top-line results from the phase 3 JADE REGIMEN study offer additional data in support of Pfizer's investigational oral once-daily Janus kinase 1 (JAK1) inhibitor for atopic dermatitis (AD). The 52-week study looked at patients 12 and older wi
- Cosentyx Shows Early Synovitis Reduction in PsAhttps://practicaldermatology.com/news/cosentyx-shows-early-synovitis-reduction-in-psa/2460600/Cosentyx (secukinumab) showed early reduction of synovitis in psoriatic arthritis (PsA), according to the Phase IIIb ULTIMATE trial which will be presented at the American College of Rheumatology (ACR) All-Virtual Annual Meeting. Specifically, a significant reduction of synovitis&n
- New from Lutronic: Accufit for Muscle Stimulationhttps://practicaldermatology.com/news/new-from-lutronic-accufit-for-muscle-stimulation/2460599/Lutronic is launching Accufit, a new device for targeted muscle activation. Eight IntelliSTIM electrodes distribute energy and generate strong muscular contractions on any area needed to be treated without pain or skin sensitivity. Accufit's IntelliPhase waveforms produce four